Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $425.63, for a total value of $1,702,520.00. Following the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $55,331.90. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Trading Up 1.2%

UTHR opened at $443.44 on Friday. The stock’s fifty day simple moving average is $353.34 and its 200 day simple moving average is $318.06. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $444.57. The stock has a market cap of $20.00 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 6.68 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period last year, the firm earned $5.85 earnings per share. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors have recently modified their holdings of the stock. F m Investments LLC increased its stake in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. HB Wealth Management LLC boosted its holdings in shares of United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. Hohimer Wealth Management LLC increased its stake in shares of United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock valued at $3,900,000 after purchasing an additional 37 shares during the last quarter. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after buying an additional 39 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research reports. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. UBS Group boosted their price objective on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a report on Monday. Royal Bank Of Canada started coverage on United Therapeutics in a research report on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Finally, Morgan Stanley reduced their price target on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Ten analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.